CA9 and neoplasm: This suggests that the CA9-DATE treatment strategy can benefit from combinatorial tumor targeting strategies such as CAR T therapies or oncolytic viruses, including those that are engineered to secrete bifunctional T cell engagers (73–75), targeting additional GBM tumor associated antigens along with CA9.